



Supplemental Figure S1

(a)




(b)



Supplemental Figure S1.

(a and b) Screening and optimization of the BiFC assay to determine vPIC component interactions. Each indicated combination of the expression plasmids were co-transfected into 293T cells by the calcium phosphate method and single samples were assessed by flow cytometry. The negative control (Neg. Cont.) consisted of non-transfected cells, and the positive control (Pos. Cont.) comprised cells co-transfected with p65-mKGN (pCONT-1) and p50-mKGC (pCONT-2) expression plasmids.

Supplemental Figure S2




Supplemental Figure S2.

Confirmation of ORF18 truncated mutant protein expression.


Each indicated combination of the expression plasmids were simultaneously and independently co-transfected in order to conduct a BiFC assay (as described in Fig. 2) and a Western blot (described here). The co-transfected cells were lysed and subjected to Western blotting using anti-mKGN primary antibodies. An antibody that recognizes actin (anti-actin) was used as a loading control. The original blotting data are shown in Supplemental Figure S5.

Supplemental Figure S3

(a)



(b)




Supplemental Figure S3.

(a) BiFC assay of ORF18 block alanine-scanning mutants (ASC1mut-ASC14mut). Each mKGN-ORF18 block alanine-scanning mutant expression plasmid was co-transfected into 293T cells with ORF30-mKGC. The 293T cells were transfected with a lipofection method and three independent samples were assessed by flow cytometry. The negative control (Neg. Cont.) was non-transfected cells and the positive control (Pos. Cont.) comprised cells co-transfected with p65-mKGN (pCONT-1) and p50-mKGC (pCONT-2). Each bar and error bar indicate the average and standard deviation, respectively.

(b) Protein expression of each ORF18 block alanine-scanning mutant (ASC1mut-ASC14mut). Each mKGN-ORF18 block alanine-scanning mutant expression plasmid was co-transfected into 293T cells with ORF30-mKGC. The samples were subjected to Western blotting using anti-mKGN primary antibody. An antibody that recognizes actin (anti-actin) was used as a loading control. The original blotting data are shown in Supplemental Figure S5.

Supplemental Figure S4




Supplemental Figure S4.


S4. Protein expression of each ORF18 single alanine mutant. Each indicated combination of the expression plasmids were simultaneously and independently co-transfected in order to conduct a BiFC assay (as described in Fig. 4b) and a Western blot (described here). The cells were lysed and subjected to Western blotting using anti-mKGN primary antibodies. An antibody that recognizes actin (anti-actin) was used as a loading control. The original blotting data are shown in Supplemental Figure S5.

Supplemental Figure S5


(a)




(b)




(c)




(d)



(e)



(f)



Supplemental Figure S5

Original Western blotting data (X-ray film) of Supplemental Figure S2, S3, and S4.

(a) Original anti-mKGN blotting data of Supplemental Figure S2 upper panel.

(b) Original anti-actin blotting data of Supplemental Figure S2 lower panel.

(c) Original anti-mKGN blotting data of Supplemental Figure S3b upper panel.




(d) Original anti-actin blotting data of Supplemental Figure S3b lower panel.

(e) Original anti-mKGN blotting data of Supplemental Figure S4 upper panel.





(f) Original anti-actin blotting data of Supplemental Figure S4 lower panel.

Supplemental Figure S6




(a)



(b)






(c)




Supplemental
Figure S6
KSHV ORF18
structure model
predicted
by AlphaFold2

(d)




Supplemental Figure S7




Supplemental
Figure S7
KSHV ORF18-
ORF30 complex
structure model
predicted
by AlphaFold2

Supplemental Figure S8




(a)



(b)




(c)



Supplemental
Figure S8
KSHV ORF18-
ORF30 complex
structure model
predicted
by AlphaFold2
Marked with ORF18
L29, E36, H41, W170

Supplemental Figure S9




Supplemental Figure S9
KSHV ORF18- ORF30 complex
structure model predicted by AlphaFold2;
ORF18 interaction residues for
ORF30 were marked with blue cartoon.
ASC mutants (Figure5a) target amino-acids
on interaction residues are emphasized as
blue sticks and tags.


ORF18	: Main chain
ORF30	: Main chain
L29, E36 H41, W170	: Main chain
	: Side chain
ORF18 interaction sites for ORF30	
	: Main chain
	: Side chain

Supplemental Figure S10


(a)



(b)



(c)



Supplemental Figure S10

Original Western blotting data (X-ray film) of Figure 5b

- (a) Original anti-FLAG blotting data of Figure 5b upper panel.
- (b) Original anti-Stag blotting data of Figure 5b Middle panel.
- (c) Original anti-FLAG blotting data of Figure 5b lower panel.

Supplemental TABLE S1: Primers for construction of expression plasmids

*c : Uppercase indicates mutagenesis sites, underlin

*^c: Uppercase indicates mutagenesis sites, underlined lowercase indicates restriction enzyme site
 *^d: Uppercase indicates N-terminal protein coding sequences, lowercase indicates C-terminal prot

a: Uppercase indicates N-terminal protein coding sequences; lowercase indicates C-terminal protein coding sequences